===== Annotation =====

{{projects:content-annotation:guess:englisht-wsj_0023-s1.png|}}
{{projects:content-annotation:guess:englisht-wsj_0023-s2.png|}}
{{projects:content-annotation:guess:englisht-wsj_0023-s3.png|}}
{{projects:content-annotation:guess:englisht-wsj_0023-s4.png|}}

===== Guesses =====

**CB:** Moleculon Inc. acquired Kalipharma for $23 million its affiliate FH Faulding & Co., an Australian pharmaceutical company said.  Kalipharma, a New Jersey-based pharmaceutical company, sells purepac label products.  Faulding said it owns 33% of Moleculon's voting stock and has an agreement to acquire an additional 19%.  That stake in preferred convertible stock holdings gives Faulding the right to increase its interest to 70% of Moleculon's voting stock.

**CW:** Australian pharmaceutical company, F.H. Faulding & Company, said its affiliate, Moleculon Inc. has acquired Kalipharma Inc. for $23 million.  Kalipharma, a New Jersey-based pharmaceutical concern, sells its various products under the Purepac label.  Faulding said it owns 33% of Moleculon's voting stock and has the agreement to acquire an additional 19%.  That stake, associated with convertible, preferred stock holdings, gives Faulding the right to increase its interest in Moleculon's voting stock to 70%.


===== Original Article =====

F.H. Faulding & Co., an Australian pharmaceuticals company, said its Moleculon Inc. affiliate acquired Kalipharma Inc. for $ 23 million. Kalipharma is a New Jersey-based pharmaceuticals concern that sells products under the Purepac label. Faulding said it owns 33% of Moleculon's voting stock and has an agreement to acquire an additional 19%. That stake, together with its convertible preferred stock holdings, gives Faulding the right to increase its interest to 70% of Moleculon's voting stock.